StromaShield:
Evolutionary innovations to stop cancer escape

A transformative approach to endow patient’s own cells to prevent cancer spread.

Evolutionary Medicine: Developing therapy inspired by nature’s own solutions

StromaShield is one-of-its kind, revolutionary approach to prevent cancer malignancy for early detected cancers. We are inspired by our discovery of why certain mammals can prevent cancer malignancy entirely, preventing cancer from spreading in their body.

StromaShield recreates what nature has perfected over millions of years. In cows and horses, cancer does not spread. Cancer stays in its primary location, and the animal does not suffer or die.

Over a decade of discovery, we have identified key genes, which provide this protection in these mammals. The stroma in these animals have evolved to make them highly resistant to cancer invasion. Recapitulating it in human cancer patients, we are developing a therapy to make cancer a benign, easily manageable disease in humans.

Our stroma-directed therapy will mimic this experiment in nature, preventing cancer to spread. The non-cancer cells will be endowed with the capacity to resist cancer invasion.

This is a transformational therapy. There is no other similar strategy in development.

Technology --- Endowing Fibroblasts to Prevent Cancer Escape

Even after chemotherapy or radiotherapy, residual cancer cells can remain, causing cancer recurrence and metastasis— the major cause of fatality.

Based on a decade of research at Yale, UCH, and UCSF, StromaShield has identified genes in stromal fibroblasts that can dramatically change their capability to “confine” cancer in its primary location.

Our technology uses patient’s own fibroblasts to transform them to prevent metastasis of cancer cells.

Minimally invasive punch (skin) biopsy will be used to isolate fibroblasts, genetically edited, and put back into the patient. The transformed fibroblasts will completely confine cancer spread, and localize its growth.

Press Coverage of our Approach

AI powered stratification

Genetics cannot explain everything about cancer malignancy. Huge variability exists between patients in their susceptibility to cancer metastasis.

For breast cancer, for example, obesity is a big risk factor as well as menopause. All patients are not alike. What works for one patient is not optimal for another.

StromaShield has developed an AI powered stratification based on evolution of vulnerability to cancer malignancy.

People

We bring decades of cumulative research in stromal biology, cancer genomics, and bio-engineering to develop a cell therapy that can target solid tumors to stop cancer escape and metastasis.

Kshitiz, Ph.D., Founder
Cancer Biology, Machine Learning, Evolution

Associate Professor in Cancer Biology UConn Health Previous:CTO, Cardiac Mimetics Ass Res Scientist, Yale University PhD, BME, Johns Hopkins Medicine B.Tech., Computer Science, IIT Bombay

GÜnter Wagner, co-Founder

Professor of Ecology & Evolutionary Biology at Yale Hagler Fellow, Texas A&M University; Fellow, University of Vienna, Austria Member, National Academy of Sciences, USA